Abstract:OBJECTIVE:To explore the effects of cannabinoid 2 receptor (CB2) in the development of bone cancer pain in mice.METHODS:A total of 84 mice (C3H/HeJ) were randomly divided into 4 groups:tumor group (Group T, n = 30), medication administration group (Group J, n = 12), vehicle group (Group D, n = 12) and sham group (Group S, n = 30). And 2 × 10(5) osteolytic NCTC2472 cells in α-MEM were injected into medullary cavity of right distal femur to induce bone cancer pain in a murine model while sham mice received an injection of only α-MEM. All mice were tested for pain-related behaviors at pre-inoculation and at Days 5, 7, 10 and 14 post-inoculation. The tests included paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). Group J and Group D were injected intrathecally with 2 µg JWH015 dissolved in 4% DMSO and only 4% DMSO respectively in a 5 µl. volume. Pain behavior tests were performed before and at 1, 6, 24, 48 and 72 h after an intrathecal injection. Lumbar intumescentia of mice in each group were harvested to examine the expression level of CB2 by Western blot after pain behavior tests at Days 5, 7, 10 and 14 post-inoculation and 12 h after an intrathecal injection.RESULTS:(1) Pain behavior tests:Mechanical allodynia appeared at Day 7 post-inoculation. The value of PWMT was (1.27 ± 0.28) g (P < 0.05) and it declined gradually to (0.53 ± 0.20) g at Day 14. The threshold of mechanical hyperalgesia increased to (1.00 ± 0.20) g at 6 h after an intrathecal injection of JWH015, peaked at (1.40 ± 0.39) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. Thermal hyperalgesia appeared at Day 10 post-inoculation. The value of PWTL was (16.9 ± 0.4) s (P < 0.05) at Day 10 and declined to (11.5 ± 0.7) s at Day 14 post-inoculation. The threshold of thermal hyperalgesia increased to (15.7 ± 1.9) g at 6 h after an intrathecal injection of JWH015, peaked at (18.6 ± 2.3) g at 12 h, became alleviated after 48 h and recovered to the pre-dosing levels at 72 h. (2) Western blot: From Day 5 post-inoculation, the ratio of CB2/β-actin increased gradually. Compared with the ratio of 0.190 ± 0.010 at Day 5 post-inoculation, the ratio of CB2/β-actin increased to 0.660 ± 0.010 at Day 14 post-inoculation (P < 0.05); compared with the ratio of 0.903 ± 0.006 in group D at 12 h after an intrathecal injection of JWH015, the ratio of CB2/β-actin 0.510 ± 0.010 significantly decreased (P < 0.05).CONCLUSION:The cannabinoid 2 receptor plays an important role in the formation of bone cancer pain.

Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice

Spinal Il-33/ St2 Signaling Contributes to Neuropathic Pain Via Neuronal Camkii- Creb and Astroglial Jak2-Stat3 Cascades in Mice

Spinal High-Mobility Group Box 1 Contributes to Mechanical Allodynia in A Rat Model of Bone Cancer Pain

[Express] Roles of TNF-α and IL-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1.

Roles of tumor necrosis factor-α and interleukin-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1

[Effects of intrathecal injection PI3K antagonist on inflammatory cytokines in spinal cord of bone cancer pain model in rats].

Schwann Cell-Derived CXCL2 Contributes to Cancer Pain by Modulating Macrophage Infiltration in a Mouse Breast Cancer Model

Role of spinal cord TNF-α in the development of bone cancer pain in mice

Spinal Astrocyte-Derived Interleukin-17A Promotes Pain Hypersensitivity in Bone Cancer Mice

Role of the CXCR4/ALK5/Smad3 Signaling Pathway in Cancer-Induced Bone Pain

Participation of spinal CaMKII-NR2B signal pathway in the development of bone cancer pain in mice

Intrathecal Injection of Metabotropic Glutamate Receptor Subtype 3 and 5 Agonist/Antagonist Attenuates Bone Cancer Pain by Inhibition of Spinal Astrocyte Activation in a Mouse Model

Stage-dependent Anti-Allodynic Effects of Intrathecal Toll-like Receptor 4 Antagonists in a Rat Model of Cancer Induced Bone Pain

Expression of spinal PD-L1 in bone cancer pain model mice and its effect on pain behaviors

Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model.

Spinal Ifn-Gamma-Induced Protein-10 (Cxcl10) Mediates Metastatic Breast Cancer-Induced Bone Pain By Activation Of Microglia In Rat Models

STING suppresses bone cancer pain via immune and neuronal modulation

Activation of the STING Pathway Induces Peripheral Sensitization Via Neuroinflammation in a Rat Model of Bone Cancer Pain.

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Role of Cannabinoid 2 Receptor in the Development of Bone Cancer Pain

Decreased sensory nerve excitation and bone pain associated with mouse Lewis lung cancer in TRPV1-deficient mice